Shareholders of Goldline Pharmaceutical approved all eight resolutions at its 22nd annual general meeting held on August 29, 2026. The vote included adopting financial statements for FY26 and authorizing material related-party transactions.

The meeting, convened in Nagpur, saw voting rights reckoned as of August 22, 2026. A total of 17 members cast votes representing 5,866,994 shares, accounting for approximately 61.11% of the outstanding shares. All resolutions secured unanimous support from the voting members, with zero votes cast against any agenda item.

Key Resolutions Passed

The shareholders approved several critical corporate actions through ordinary and special resolutions:

• Adoption of standalone and consolidated audited financial statements for the year ended March 31, 2026.
• Declaration of dividend on preference shares for FY26.
• Re-appointment of Mr. Prashant Shrikrishna Karkare as a director retiring by rotation.
• Approval of existing and new material related-party transactions with Activista Healthcare Private Limited, Nucleage Pharma Solutions Private Limited, and Numerius Healthcare Private Limited.

Capital Structure Changes

Two special resolutions required a higher majority threshold were also passed unanimously by those who voted:

1. Borrowing of unsecured loans from directors with an option of convertibility into equity shares.
2. Approval of loans, investments, guarantees, or security under Section 185 of the Companies Act, 2013.

What the Numbers Show

The voting data reveals a significant concentration of participation among promoter entities. While only 17 individual members cast valid votes, they represented over 58.6 lakh shares. Notably, for resolutions involving related-party transactions (Resolutions 4, 5, and 6), the promoter group's votes were marked as invalid due to conflict of interest, yet the resolutions still passed with 100% support from the remaining eligible public shareholders. This indicates strong alignment between the promoters and public investors on these strategic approvals, despite the regulatory requirement to exclude interested parties from the count.

Goldline Pharmaceutical reported a 45% year-on-year increase in net profit for FY26, reaching ₹411.71 lakhs. The Nagpur-based pharma firm also saw its revenue from operations and other income rise by 11% to ₹3,119.88 lakhs during the period.

The results were presented to shareholders at the company’s 22nd Annual General Meeting held on August 29, 2026, in Nagpur. This marks the first AGM since Goldline Pharmaceutical listed its equity shares on the BSE SME Platform in May 2026.

Financial Performance

Whole-Time Director Swapan Khandelwal outlined the financial highlights for the fiscal year ended March 31, 2026. The company’s Profit Before Tax (PBT) grew significantly from ₹385.84 lakhs in FY25 to ₹538.54 lakhs in FY26.

The Earnings Per Share (EPS) improved from ₹4.11 to ₹5.97, reflecting the stronger bottom-line performance.

What the Numbers Show

The divergence between revenue growth and profit expansion indicates improved operational efficiency or cost management. While top-line revenue increased by approximately 11%, pre-tax profits surged nearly 40%. This suggests that gross margins expanded or operating expenses were controlled effectively relative to sales growth, allowing a larger portion of incremental revenue to flow through to the bottom line.

Governance and Dividends

Shareholders approved several key resolutions, including the adoption of standalone audited financial statements and the re-appointment of Executive Director Prashant Karkare. The Board also declared a dividend of ₹12 per preference share of face value ₹100 each for FY26.

Special business items included approvals for material related-party transactions with Activista Healthcare Private Limited, Nucleage Pharma Solutions Private Limited, and Numerius Healthcare Private Limited. Additionally, members approved the borrowing of unsecured loans from directors, with an option for conversion into equity shares.

Future Outlook

Executive Director Prashant Karkare highlighted the company’s focus on strengthening its product portfolio and expanding geographical presence. Management plans to explore opportunities in specialty and super-specialty segments while enhancing engagement with the medical fraternity.

Chairman & Managing Director Amol Mujumdar emphasized that the recent listing has strengthened the financial foundation and enhanced capital market visibility. The company remains committed to sustainable value creation through disciplined execution and regulatory compliance.